Elanco Animal Health Incorporated Common Stock (ELAN)
10.80
-0.51 (-4.51%)
Elanco Animal Health Inc is a global leader in the development and manufacturing of products for animal health and well-being
The company focuses on providing innovative solutions for companion and livestock animals, which include a wide range of vaccines, pharmaceuticals, and nutritional products designed to prevent and treat diseases. By combining science and technology, Elanco aims to enhance animal care and improve food safety while promoting sustainable farming practices. With a commitment to animal health and welfare, the company partners with veterinarians, farmers, and pet owners to deliver effective health management solutions.
Animal health company Elanco (NYSEELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $4.48 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $0.14 per share was in line with analysts’ consensus estimates.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Elanco Animal Health Incorporated (NYSEELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Elanco is an “animal health company that develops, manufactures, and markets products for pets and farm animals.”
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSEELAN) and reminds investors of the December 6, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSEELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco To Contact Him Directly To Discuss Their Options
PHILADELPHIA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Elanco Animal Health (“Elanco” or the “Company”) (NYSEELAN) on behalf of purchasers of ELANCO securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”).
LOS ANGELES, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSEELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSEELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elanco Animal Health Inc. (“Elanco” or the “Company”) (NYSEELAN) on behalf of purchasers of Elanco securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”).
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSEELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
